Upcoming Studies

Upcoming Studies

We have the following upcoming studies:


    1. Basidiomycete mushroom nutritional supplement on safety, fatigue, and inflammation in breast cancer patients undergoing taxane-based chemotherapy
    2. Vitamin D supplementation in healthy, elderly individuals
    3. Laser therapy treatment of peripheral neuropathic pain in individuals with type 2 diabetes

1. Basidiomycete mushroom nutritional supplement on safety, fatigue, and inflammation in breast cancer patients undergoing taxane-based chemotherapy
The purpose of this study is to determine the safety and tolerability of basidiomycete mushroom in female breast cancer patients undergoing adjuvant taxane-based chemotherapy. We will determine if AHCC is safe and tolerable in patients receiving chemotherapy and if it can impact quality of life and inflammation by ameliorating common side effects such as fatigue, nausea, vomiting, or neuropathic pain. Subjects will be assessed at baseline (visit 1, week 0), visit 2 (week 6), and visit 3 (week 12) on NCI common adverse events, treatment adherence, CBC, INR, liver function tests, the EORTC quality of life questionnaire core cancer module (QLQ-C30) and Breast Module (BR-23 Breast), NK cell activity, and a cytokine 4-plex panel (TNF-a, IL-1β, IL-6, and IL-10).

2. Vitamin D supplementation in healthy, elderly individuals
The purpose of this study is to the effect of a vitamin D emulsion on serum vitamin D levels in healthy, elderly people 60 years of age and older. We will determine if this formula is superior to placebo on serum vitamin D and secondary outcome measures, such as body composition and quality of life. Subjects will be assessed at baseline, visit 2 (week 4), and visit 3 (week 8) on serum vitamin D, body composition (body fat, BMI, waist to hip ratio), and the SF-36 quality of life questionnaire.

3. Laser Therapy Treatment of Peripheral Neuropathic Pain in Individuals with Type 2 Diabetes
This study is a randomized, double-blinded factorial trial to evaluate the efficacy of a course of laser therapy on peripheral neuropathic pain in persons with type 2 diabetes. Participants will be assessed at baseline, post-intervention, and 3-months follow-up, and the study will consist of two treatment arms, including: (a) once-per-week laser treatment for 12 weeks or (b) once-per-week sham (or placebo) treatment for 12 weeks. Additionally, the study will examine inflammatory markers, functional status, and quality of life.